Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Antibiotic Incentives Helped Spero Get Where It Is Today

Executive Summary

The firm is developing a novel class of antibacterials that could enable shelved agents for Gram-positive infections to reach and kill Gram-negative bacteria.


Related Content

Choice Of Regulatory Pathway Is Key Inflection Point In Drug Reviews
Senate 'Cures' Companion Advances; Funding Unclear
Global Fund For Antimicrobial Resistance Proposed, Financing Unclear
Spero Therapeutics LLC
With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation


Related Companies

Related Deals